ArticleFrontiers in artificial intelligence2025
The potential of DeepSeek for AI-aided diagnosis of antibody-positive autoimmune encephalitis: a single-center, retrospective, observational study.
Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence for pediatric neuroimaging.Pediatric radiology · 2026Review
- Preliminary evaluation of DeepSeek-R1 and GPT-5.3 in selected PET/CT clinical scenarios: patient preparation, report interpretation, and diagnostic reasoning.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune encephalitis (AIE) is challenging to diagnose, especially in primary hospitals in China with limited medical resources. DeepSeek, a newly developed AI, shows potential as a cost-effective tool for improving diagnostic efficiency. However, no studies have evaluated the diagnostic accuracy of DeepSeek for AIE. Methods: This retrospective study included 100 patients with anti-neuronal antibody-positive AIE treated at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. After removing personally identifiable information, antibody results, and history of immunotherapy from patients' medical histories, the following information was sequentially input into DeepSeek: sex, age, chief complaint, medical history, EEG findings, head MRI description, and cerebrospinal fluid (CSF) results. The positive rates of AIE diagnoses predicted by DeepSeek were then categorized as most likely diagnosis, differential diagnosis, and total diagnosis. Results: Using DeepSeek, the probabilities of AIE appearing as the most likely diagnosis and total diagnosis accuracy were 49 and 65%. When patient data were input stepwise, both the total diagnosis accuracy and the most likely diagnosis accuracy did not significantly increase. AIE patients with anti-MOG and anti-GABAbR positivity had predicted total diagnostic positivity rates of 88 and 100%, respectively. Patients presenting with headache and epilepsy were more likely to be diagnosed with AIE (96 and 100%). Conclusion: DeepSeek shows limited positive diagnostic accuracy for predicting the diagnosis of AIE. The application of this new AI technology could be used to promote early screening for AIE in primary hospitals in China, improve medical education, and lead to research advances in AIE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.